Aarti Drugs shares fall marginally after the company received seven observations from the United States Food and Drug Administration (USFDA).
At 09:40am, Aarti Drugs was quoting at Rs 523.60, down Rs 1.20, or 0.23 percent, on the Bombay Stock Exchange.
The company has received seven inspection observations in 'Form 483' after USFDA inspected the API manufacturing facility at Plot No. E-22, MIDC, Tarapur, Maharashtra between 12-20 September, 2024.
None of the observations are related to data integrity and there is no impact on the financial, operation or other activities of the company under the observations received, the company said.
Catch all the market action on our live blog
In August the company board approved the buyback of up to 6.65 lakh shares of the face value of Rs 10 each (Rs 59.85 crore), representing up to 0.72 percent of the total paid-up equity shares of the company, at Rs 900 per equity share.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
